Financials
Financial year 2024
Equiservices and clinical trials from Meise, company number BE0641815841, closed financial year 2024 with a result of € 11,912 after tax. For that financial year Equiservices and clinical trials recorded a gross margin of € 24,063 and equity of € 17,139. Compared with financial year 2023, the result moved from € 20,431 to € 11,912. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2025.
€ 17,139
▲ 228% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 11,912
▼ 42% vs 2023
Profit after tax over the fiscal year.
€ 51,533
▼ 18% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 10,939.
People and assets in 2024
€ 144
▼ 70% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 72,120
▼ 14% vs 2023
Loans from banks and other lenders, long and short.
€ 6,726
▲ 75% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 23,777
▲ 39% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 8,803 | € 7,075 | € 35,755 | € 24,063 | ▼ 33% |
| Profit after taxes | € 3,945 | € 1,604 | € 20,431 | € 11,912 | ▼ 42% |
| Equity | € -16,807 | € -15,203 | € 5,228 | € 17,139 | ▲ 228% |
| Total debts | € 50,208 | € 142,265 | € 127,441 | € 112,744 | ▼ 12% |
| Cash | € 10,092 | € 72,245 | € 62,908 | € 51,533 | ▼ 18% |
| Land & buildings | - | € 27,425 | € 42,255 | € 40,950 | ▼ 3% |
| Retained profit | € -23,007 | € -21,403 | € -972 | € 10,939 | ▲ € 11,912 |
| Bank debt | € 0 | € 96,120 | € 84,120 | € 72,120 | ▼ 14% |
| Balance sheet total | € 33,401 | € 127,062 | € 132,669 | € 129,883 | ▼ 2% |
Key figures of Equiservices and clinical trials, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Equiservices and clinical trials?
What happened at Equiservices and clinical trials in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 11,912 (▼ 42% vs 2023). filed late Source: NBB ↗
- New establishment in Meise. KBO
- Start of the company according to the CBE. KBO
In short
From € 3,945 profit in 2021 to € 11,912 profit in 2024.
Paid € 15,629 in corporate taxes since 2021.
Best year ever: 2023, with € 20,431 profit.
Management
Behind Equiservices and clinical trials are Fabienne Eggermont and Nicolas Cartilier.
Directors
According to the 2024 annual accounts
Fabienne Eggermont
Director
Nicolas Cartilier
Director
Establishments
Establishment units
Physical locations of this company
Willem de Zwijgerlaan 12
1860 Meise
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0641.815.841
- VAT number
- BE 0641.815.841
- Registered office
- Willem de Zwijgerlaan 12, 1860 Meise
- Names & denominations
- Equiservices and clinical trials · ESCT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 October 2015
- Peppol
- Active · Active since 4 Sept 2025
- Contact
- [email protected] +32473899842
- Activities · NACE
Activiteiten van medisch specialisten
Pensions voor huisdieren
Goederenvervoer over de weg
Overige sportactiviteiten, neg
Exploitatie van sportaccommodaties